Lentigo maligna is a type of melanoma in situ, meaning cancerous melanocytes are confined to the outermost layer of skin (the epidermis) and have not yet invaded deeper tissue. It typically appears as a slowly expanding, irregularly pigmented flat patch on sun-damaged skin, most often on the face, ears, or scalp. Left untreated, it can progress to lentigo maligna melanoma, an invasive form that carries real metastatic potential. The distinction between the two stages matters enormously for prognosis and treatment.
Who Gets Lentigo Maligna and Why It Is Becoming More Common
Lentigo maligna overwhelmingly affects people with fair skin who have accumulated decades of sun exposure. It is most common in older adults, and its incidence has been climbing steadily in multiple countries over the past few decades. In the United States, the age-standardized incidence of lentigo maligna rose from about 4.2 to 5.6 per 100,000 person-years between 2000 and 2019, while the invasive form (lentigo maligna melanoma) climbed from about 1.3 to 2.4 over the same period.1PubMed. Incidence trends of lentigo maligna and lentigo maligna melanoma in the United States from 2000 to 2019 The Netherlands saw even steeper rises, with lentigo maligna incidence jumping from 0.72 to 3.84 per 100,000 between 1989 and 2013. Researchers there concluded the trend reflects a genuine increase, not just more awareness or biopsy sampling.2PubMed. Epidemiology of Lentigo Maligna and Lentigo Maligna Melanoma in the Netherlands, 1989-2013
Men are affected more often than women, and the gap widens with age. In England, the male-to-female ratio for lentigo maligna reaches about 2-to-1 among people aged 80 and older. Head-and-neck tumors are far more common in men, with an odds ratio of roughly 1.8, which has led researchers to suggest that hair acts as a protective factor against the cumulative UV damage that drives the disease.3British Journal of Dermatology. Epidemiology of lentigo maligna and lentigo maligna melanoma in England between 2013 and 2023 Fair skin and cumulative ultraviolet exposure remain the most firmly established risk factors overall.4Clinical and Experimental Dermatology. Lentigo maligna: a review
What It Looks Like and How Doctors Tell It Apart From Other Spots
To the naked eye, lentigo maligna looks like a flat, tan-to-brown patch with irregular borders and uneven color. It tends to grow slowly outward over months to years, sometimes reaching several centimeters across before anyone brings it up with a doctor. Because it arises on chronically sun-damaged skin, it shares real estate with a whole lineup of benign brown spots, including solar lentigines (age spots), seborrheic keratoses, and pigmented actinic keratoses. This overlap makes diagnosis tricky, especially on a face already covered in sun-related lesions.
Dermoscopy, a handheld magnification technique, helps enormously. When dermatologists look at a suspected lentigo maligna under magnification, specific patterns raise or lower the probability. Grey rhomboid structures (diamond-shaped grey areas around hair follicles) are the strongest predictor, increasing the probability about sixfold. Follicle openings that appear obscured or obliterated also raise suspicion. Meanwhile, white circles, surface scales, and red coloring steer the diagnosis toward pigmented actinic keratosis instead.5British Journal of Dermatology. Dermoscopic clues to differentiate facial lentigo maligna from pigmented actinic keratosis A separate dermoscopic scoring system found that if even one of four key features is present, including brown globules, necklace-like pigment network, atypical pigment network, or blue-grey ribbon-like structures, sensitivity for detecting lentigo maligna reaches about 99% while specificity sits near 84%.6PubMed. Correlation between digital epiluminescence microscopy parameters and histopathological changes in lentigo maligna and solar lentigo
Despite these tools, biopsy remains the gold standard for confirmation. The clinical challenge is that a biopsy of one part of a large lesion may miss the area where invasion has already begun, which is one reason that dermatologists sometimes take multiple samples from different zones of a big patch.
Conditions That Can Mimic Lentigo Maligna
The face of an older adult with extensive sun damage can host a variety of pigmented lesions that look surprisingly similar to lentigo maligna. Solar lentigines are the most common imitator, but pigmented actinic keratoses and flat seborrheic keratoses also cause confusion. Rarer mimics exist as well. A case report described actinic lichen planus on the forehead presenting as a dark, irregularly bordered patch with dermoscopic features that strongly resembled lentigo maligna, including an irregular brownish network. Biopsy revealed a completely different pathology, with features like melanin incontinence and perivascular lymphocytic infiltrates pointing to lichen planus rather than melanocytic disease.7PubMed Central. Actinic Lichen Planus of the Forehead Mimicking Lentigo Maligna: A Case Report and Literature Review The broader lesson is that not every suspicious pigmented patch on sun-damaged skin is lentigo maligna, and biopsy is essential for any lesion that cannot be confidently diagnosed by dermoscopy alone.
How Likely Is Progression to Invasive Melanoma
This is the question that drives the urgency behind treating lentigo maligna. The condition is melanoma in situ, and it has real potential to become invasive lentigo maligna melanoma if the abnormal melanocytes breach the basement membrane and grow into the dermis. Once that happens, the cancer can potentially spread to lymph nodes and distant organs.
Estimating the exact progression rate is difficult because most lentigo maligna lesions are treated before researchers can observe what would happen without intervention. One study estimated the annual risk of progression to invasive melanoma at about 3.5%, which works out to an average timeline of roughly 28 years for an untreated lentigo maligna to become invasive.8PubMed. Estimated risk of progression of lentigo maligna to lentigo maligna melanoma That 28-year average might sound reassuring, but it obscures wide individual variation. Some lesions progress much faster, and there is no reliable way to predict which ones will. This uncertainty is why physicians generally recommend treatment rather than watchful waiting, even in older patients.
What Makes Lentigo Maligna Genetically Distinct
At the molecular level, lentigo maligna carries hallmarks of melanoma driven by chronic sun damage. Studies of its mutational landscape reveal a high mutational burden with a dominant ultraviolet-radiation signature, along with copy number alterations and defects in DNA repair and cell-cycle checkpoint genes. When lentigo maligna recurs, the mutational profile shares features not only with melanomas from chronically sun-exposed sites but also with later-stage melanomas in general.9PubMed. Evaluation of clonality in lentigo maligna This finding matters because it suggests that recurrent lentigo maligna may have a more aggressive biology than the original lesion, adding urgency to achieving clear margins at the first surgery.
Surgical Treatment and the Margin Challenge
Surgery is the primary treatment for lentigo maligna, but it comes with a headache that other melanoma subtypes mostly avoid: the lesion’s true borders are almost invisible. Lentigo maligna frequently extends well beyond what the eye can see, with individual malignant melanocytes scattered along the sun-damaged epidermis far from the clinically apparent patch. Standard wide local excision with a fixed margin (usually 5 to 10 millimeters) can miss these invisible extensions, leading to incomplete removal and recurrence.
Staged excision techniques address this by checking the entire surgical margin under a microscope before the wound is closed. In one approach known as geometric staged excision, a study of 239 patients found a recurrence rate of just 1.7% over an average follow-up of about 32 months.10JAMA Dermatology. Geometric Staged Excision for the Treatment of Lentigo Maligna and Lentigo Maligna Melanoma: A Long-term Experience With Literature Review Another series of 100 patients treated with staged excision and full immunohistochemical margin assessment reported a 4% recurrence rate after a mean follow-up of five years, with recurrences appearing between three and six-and-a-half years out.11British Journal of Dermatology. Recurrence rate of lentigo maligna after micrographically controlled staged surgical excision Slow Mohs surgery, a variant that uses permanent sections and immunohistochemical stains instead of the frozen sections used in traditional Mohs, has shown a recurrence rate of about 3% with a curative rate of roughly 97%.12PubMed Central. Comparative Analysis of Slow Mohs Surgery in Melanoma and Mohs Micrographic Surgery in Squamous Cell Carcinoma and Basal Cell Carcinoma
A large database analysis comparing Mohs micrographic surgery to standard wide local excision found significantly better survival outcomes with Mohs, including a 10-year disease-specific survival of 95% versus 91% for wide local excision.13Oxford Academic. Surviving by a margin: Mohs outperforms wide local excision for lentigo maligna These numbers are encouraging but come with a caveat: staged excision techniques require specialized dermatopathology support and multiple days of surgery and analysis, making them less available in many settings.
Margin Assessment With Special Stains and Newer Technology
Part of what makes staged excision effective is the use of immunohistochemical stains, special markers that make individual melanocytes visible under the microscope even in heavily sun-damaged skin where they are otherwise difficult to distinguish from background cells. Markers like SOX10 and Melan A help pathologists count melanocyte density at the surgical margins, which is critical for determining whether the lesion has truly been cleared.14British Journal of Biomedical Science. Double Immunohistochemical Labelling of PRAME and Melan A in Slow Mohs Biopsy Margin Assessment of Lentigo Maligna and Lentigo Maligna Melanoma Without these stains, isolated tumor cells at the margin can easily be missed.
A more recent technology, reflectance confocal microscopy, allows clinicians to examine the skin at a cellular level in real time, without cutting tissue. A systematic review and meta-analysis of confocal microscopy for lentigo maligna margin mapping found sensitivity of about 91%, specificity around 96%, and overall agreement with histopathology of about 92%.15PubMed. Reflectance confocal microscopy for margin mapping of melanoma of the lentigo maligna type: A systematic review and meta-analysis A prospective study comparing confocal microscopy margin maps to final histopathology in staged excision found agreement of about 86%.16PubMed Central. Lentigo maligna melanoma mapping using reflectance confocal microscopy correlates with staged excision: A prospective study The appeal is that confocal microscopy could potentially allow surgeons to map the lesion’s true extent before cutting, reducing the number of surgical stages needed. The meta-analysis found patients averaged only about 1.2 stages to achieve clear margins when confocal microscopy was used for pre-operative mapping.
Non-Surgical Alternatives
Not everyone with lentigo maligna is a good candidate for surgery. The typical patient is elderly, and the lesion is often on the face. A large excision on the nose, cheek, or temple of a frail 85-year-old carries cosmetic, functional, and medical risks that may outweigh the slow-moving threat of the tumor. Two non-surgical options have accumulated meaningful evidence: topical imiquimod cream and radiation therapy.
Topical Imiquimod
Imiquimod is an immune-stimulating cream applied directly to the skin. A systematic review pooling data from 347 tumors across 45 studies found a histologic clearance rate of about 76% and a clinical clearance rate of about 78%, with a clinical recurrence rate of roughly 2% over an average follow-up of about 34 months.17Journal of the American Academy of Dermatology. A quantitative systematic review of the efficacy of imiquimod monotherapy for lentigo maligna and an analysis of factors that affect tumor clearance The review also found that treatment duration matters: applying imiquimod more than 60 total times, or more than five times per week, was associated with an eightfold higher odds of achieving histologic clearance compared to less intensive regimens. One cohort of 57 patients treated with daily imiquimod for 12 weeks showed complete clinical clearance in about 84%.18PubMed. Effectiveness of 5% Topical Imiquimod for Lentigo Maligna Treatment
A significant limitation, though, is that clinical appearance does not reliably predict whether the tumor is truly gone at a microscopic level. In one study of 43 patients who used imiquimod before undergoing planned excision, only about 53% had confirmed histologic clearance, even when the skin looked completely clear clinically. Seven patients whose skin appeared clear still had tumor present on histology, and conversely, seven patients whose skin still looked abnormal turned out to be tumor-free.19JAMA Dermatology. Efficacy of Imiquimod Cream, 5%, for Lentigo Maligna After Complete Excision This disconnect means that using imiquimod alone, without a follow-up biopsy or excision, requires accepting real uncertainty about whether the job is done. Some patients also struggle with the treatment itself, which causes intense redness, swelling, and sometimes significant pain at the application site.
Radiation Therapy
Radiation is considered the preferred non-surgical treatment for lentigo maligna, offering good local control and generally acceptable cosmetic results.20PubMed Central. Radiotherapy for lentigo maligna and lentigo maligna melanoma – a systematic review A single-center study of 91 patients (67 with lentigo maligna, 24 with lentigo maligna melanoma) treated with radiation found recurrences in about 15% over a mean follow-up of roughly 25 months.21PubMed. Radiation therapy on lentigo maligna: A single-centre retrospective study on 91 patients The recurrence rates were similar in the in-situ and invasive groups, at about 15% and 17% respectively. While that 15% is higher than what staged surgery achieves, radiation remains a reasonable option when surgery is not feasible.
One factor that can tip the scale between imiquimod and radiation is cost and logistics. Healthcare system costs per patient are dramatically higher for radiation (about $2,673) than for imiquimod (about $73), and radiation typically requires far more treatment visits, averaging around 27 sessions compared to about 6 for imiquimod. When lost productivity and travel are factored in, the total societal cost of radiation is roughly six times that of imiquimod.22PubMed Central. A cost comparison of radiotherapy and topical imiquimod for lentigo maligna treatment: Considerations for clinical decision-making For a frail elderly patient, the burden of traveling to a radiation facility nearly 30 times is not trivial.
Recurrence and Follow-Up
Even after apparently successful treatment, lentigo maligna can come back. A nationwide Dutch study found an overall five-year recurrence rate of about 7% across all treatment types. The split between surgical and non-surgical approaches was stark: surgery carried a five-year recurrence rate of 6%, while non-surgical treatments came in at roughly 24%. The median time to recurrence was about 2.4 years, but some recurrences appeared as late as five years out.23British Journal of Dermatology. A nationwide study of treatment of lentigo maligna and its recurrence rate in the Netherlands A smaller single-practice study with a notably long median follow-up of nearly 12 years found a recurrence rate of about 6% after staged excision, with an average surgical margin of 7 millimeters needed to achieve clearance.24PubMed Central. Staged Excision for Lentigo Maligna and Lentigo Maligna Melanoma: Analysis of Surgical Margins and Long-term Recurrence in 68 Cases from a Single Practice
The fact that recurrences can emerge years after treatment means that follow-up surveillance needs to be sustained. Most dermatologists recommend clinical and dermoscopic monitoring at least annually for years afterward, with closer monitoring in the first two to three years when recurrences are most likely.
Reconstruction After Facial Surgery
Because lentigo maligna typically grows on the face and can spread invisibly across large areas, the surgical defect left after complete removal is often larger than patients expect. Primary closure, simply stitching the wound edges together, is frequently impossible. Patients may require local skin flaps, skin grafts, or even tissue expansion techniques to repair the defect.25PubMed. Surgical reconstruction of lentigo maligna defects Preoperative counseling that prepares patients for this possibility is considered essential, since the final defect size is often not known until all surgical stages are complete. Research on patient decision-making highlights that people want clear information up front about potential scarring, recovery time, side effects, and the number of follow-up visits any treatment path will require.26Skin Health and Disease. Co-design of a decision aid for the management of lentigo maligna in older and frailer adults The cosmetic and emotional impact of facial surgery for a lesion that may have looked like “just a brown spot” can be significant, and these concerns are worth discussing before treatment decisions are finalized.
When Treatment Decisions Get Complicated
The evidence clearly favors staged surgical excision as the most effective treatment, but real-world decision-making is rarely that tidy. The typical lentigo maligna patient is in their seventies or eighties, often with other health conditions that make prolonged multi-stage surgery under local anesthesia a genuine burden. A very large lesion on the nose or eyelid may require extensive reconstruction that affects vision or breathing. Some patients are on blood thinners that complicate wound healing. Others live far from a center that offers staged excision with the necessary dermatopathology infrastructure.
In these situations, treatment becomes a balancing act between the oncologic ideal and what the patient can realistically tolerate. Imiquimod may be appropriate for a patient who cannot undergo surgery, even though its histologic clearance rate is lower, because the alternative of no treatment at all carries an ongoing annual risk of progression. Radiation offers better local control than imiquimod but requires many visits. Observation alone, while not standard, is occasionally a defensible choice for a very frail patient with a small, slowly changing lesion whose life expectancy is short enough that invasive progression is unlikely to cause harm. There is no single right answer, and the best treatment plan depends on the specific person as much as the specific lesion.